Hi Guys back of Holiday but not yet really settled down. Needed the break as I havent had a holiday in 5 years. Just been resting up at home.

Back to the stocks. Well lets face it last week was a stinker, simple as that. Interest rates hike hanging over the market and the tiddlers getting hurt most as all of the extra cost will fall to the bottom line. Lets hope for a better week.

Update on stocks.

I D DATA- hoping for this one to carry on from Friday and start to rise again. About 4 weeks to results so we may get a good run plus a contract win is get to be confirmed.

INCITE HOLDINGS - strange happenings at this company last week but apparantley big orders were being filled for institutional players, in fact a pal of mine on another site who is a big holder was contacted to see if he wanted to sell any of his holding and he gave them a quick no chance answer.

BEMA GOLD - fell back by about 10 points last week on averageish results. Fact of the matter is that a Miner should be judged on NAV and not earnings, due to physical nature of the business.

JUST CAR CLINICS - TA uptrend in place and company released two very interesting pieces of news on its web site that should see further support.

CENTURION ELECTRONICS - gave back a bit of ground last week but uptrend trully in place.

HCEG - another that gave ground back last week but there was some good news later in the week refering to warrants. Seems holders on a certain date will be awarded a warrant for every XXX share held . Ask me in the morning.

PIPEX - changed name last week had an up and down week but I added yet again. Great growth potential here.

NEW RECOMMENDATION

Going to go in for SCI ENTERTAINMENT SEG in the morning. Saturday paper confirmed that trading was well in front of budget and this backed up what Evil Knievil had been saying last week. EK feels that this is one of the cheapest stocks on the Whole Market, and we should get a good run up to Xmas with the new Desert Storm offering (sorry not an expert on games).
DYOR and if you buy watch the spread in the first hour or so, the MMS read the newspapers just like us, dont get sucked in. Remember you are responsible for your own buy and sell actions, we dont want any whimps complaining if they lose money. Only use money that you camn afford to lose and remember this is investing. If you want a quick fix, I suggest you go down to your local bookies , casino or boozer and play on the one armed bandit. We are all adults.

gf.

ps, sorry forgot Service Power Tech - special update on that sometime monday.

BTG

One to put on the watch list, from monday. Has it been oversold given the following research???????.

BTG update November 16, 2003

Elric Lloyd-Langton



BTG an RNS feature on October 10, plunged to 154p from 420 a loss 59% on Friday after the FDA suspended clinical trials of its Varisolve drug.BTG said the US Food and Drug Administration (FDA) had “placed on clinical hold” a Phase II safety study of Varisolve. The news obviously came as a shock to the city, more so given that it was only two weeks ago BTG held an analysts’ briefing on Varisolve’s prospects, at which, according to one analyst present, the company “banged on and on about what a wonderful Varisolve is a non-surgical solution that injects foam into troublesome veins. The none surgical procedure ment that the world’s 150 million sufferers could have their veins treated during a lunch hour, but it also raises medical risks such as deep-vein thrombosis or air emboli.

Analysts viewed Varisolve as the company’s potential blockbuster treatment for varicose veins. Some analyists estimate Varisolve to be worth between $250 million (148 million) and $1 billion.
BTG said the company did not yet know why the FDA had halted trials of the drug, which has already passed pivotal Phase III trials in Europe with flying colours. However, she said the regulator was expected to explain its decision to Provensis, the BTG subsidiary that is developing Varisolve, within the next ten days.

Analysts said the FDA’s decision to suspend the trials was likely to delay a US launch of the drug by at least six months. Although most remained confident that the FDA’s decision related to a minor or procedural issue, some analysts pointed out that there were legitimate safety concerns with the treatment. With no explanation offered for the suspension of the trials it is difficult for investors to gauge the seriousness of the events, clearly some investor ran for the door when news broke. Given that Varisolve passed Phase III trials in Europe with flying colours it appears that investors fears are over done. It is often the case when news events such as this catch investors off guard. There is no doubt that some investors will see this news a buying opportunity for the long term, but the FDA do seem to be holding investors sentiment in their hands.


Edward Kalfayan October 10, 2003

From the BTG trading statement this morning

There are no great surprises ahead of the Interims on Dec 1. There will be a significant increase in revenues as expected, with lower operating costs reduced losses, and good progress across the portfolio.

Preliminary results from a pivotal European Phase III trial for the novel varicose vein technology VARISOLVE(R)were presented at a scientific congress in San Diego on 30 August. VARISOLVE(R) achieved an 83.4% response rate first regulatory submission in Europe as planned in 2004, with the first European launch targeted in 2005.

A Phase II trial is progressing in the US, and data from the second of three 20-patient cohorts is expected to be submitted to the US FDA by end December. Construction of a shell facility and small scale manufacturing production line continues in the UK. Discussions with potential partners have commenced


The market for providing technology commercialisation services to sources of technology and intellectual property has remained strong and 13 new technology commercialisation agreements were signed with academic and corporate sources.

Offering more developed technologies has proven to be attractive to potential licensees or venture partners, and 17 new development projects were authorised to develop technologies further prior to commercialisation.

Two compounds with the potential to treat anxiety and depression were licensed to Abiogen Pharma S.p.A. BTG will investigate BGC 9331 in a Phase I/II trial for its use as a first-line treatment for gastric cancer. BTG and Taiwan's Industrial Technology Research Institute (ITRI) will jointly develop, and BTG will commercialise, a polymer technology for information displays for use in the next generation of laptop computers, mobile phones, PDAs and television sets.

BTG seeks to leverage its core IP, technology and commercial expertise by investing in early stage technology companies with high growth potential. An investment in Cambridge-based Xention Discovery Ltd, will develop drug screening programmes in the cardiovascular and neurology areas. BTG will also be a co-sponsor of a new early stage life sciences fund based in Boston, MA.ENDS.

Has it been oversold, that is the question and its a big gamble. I will be watching very carefully early this coming week.

cheers GF.

Do you understand the dilution on HCEG Goldfinger?

How's JCR going with the interest rate rise momentum that it has to serve on it's massive debt?

Just a word to thread onlookers. The previous poster is a well known trouble maker/idiot whatever. Best to just ignore that type.

cheers gf.

BTG

One to put on the watch list, from monday. Has it been oversold given the following research???????.

BTG update November 16, 2003

Elric Lloyd-Langton



BTG an RNS feature on October 10, plunged to 154p from 420 a loss 59% on Friday after the FDA suspended clinical trials of its Varisolve drug.BTG said the US Food and Drug Administration (FDA) had “placed on clinical hold” a Phase II safety study of Varisolve. The news obviously came as a shock to the city, more so given that it was only two weeks ago BTG held an analysts’ briefing on Varisolve’s prospects, at which, according to one analyst present, the company “banged on and on about what a wonderful Varisolve is a non-surgical solution that injects foam into troublesome veins. The none surgical procedure ment that the world’s 150 million sufferers could have their veins treated during a lunch hour, but it also raises medical risks such as deep-vein thrombosis or air emboli.

Analysts viewed Varisolve as the company’s potential blockbuster treatment for varicose veins. Some analyists estimate Varisolve to be worth between $250 million (148 million) and $1 billion.
BTG said the company did not yet know why the FDA had halted trials of the drug, which has already passed pivotal Phase III trials in Europe with flying colours. However, she said the regulator was expected to explain its decision to Provensis, the BTG subsidiary that is developing Varisolve, within the next ten days.

Analysts said the FDA’s decision to suspend the trials was likely to delay a US launch of the drug by at least six months. Although most remained confident that the FDA’s decision related to a minor or procedural issue, some analysts pointed out that there were legitimate safety concerns with the treatment. With no explanation offered for the suspension of the trials it is difficult for investors to gauge the seriousness of the events, clearly some investor ran for the door when news broke. Given that Varisolve passed Phase III trials in Europe with flying colours it appears that investors fears are over done. It is often the case when news events such as this catch investors off guard. There is no doubt that some investors will see this news a buying opportunity for the long term, but the FDA do seem to be holding investors sentiment in their hands.


Edward Kalfayan October 10, 2003

From the BTG trading statement this morning

There are no great surprises ahead of the Interims on Dec 1. There will be a significant increase in revenues as expected, with lower operating costs reduced losses, and good progress across the portfolio.

Preliminary results from a pivotal European Phase III trial for the novel varicose vein technology VARISOLVE(R)were presented at a scientific congress in San Diego on 30 August. VARISOLVE(R) achieved an 83.4% response rate first regulatory submission in Europe as planned in 2004, with the first European launch targeted in 2005.

A Phase II trial is progressing in the US, and data from the second of three 20-patient cohorts is expected to be submitted to the US FDA by end December. Construction of a shell facility and small scale manufacturing production line continues in the UK. Discussions with potential partners have commenced


The market for providing technology commercialisation services to sources of technology and intellectual property has remained strong and 13 new technology commercialisation agreements were signed with academic and corporate sources.

Offering more developed technologies has proven to be attractive to potential licensees or venture partners, and 17 new development projects were authorised to develop technologies further prior to commercialisation.

Two compounds with the potential to treat anxiety and depression were licensed to Abiogen Pharma S.p.A. BTG will investigate BGC 9331 in a Phase I/II trial for its use as a first-line treatment for gastric cancer. BTG and Taiwan's Industrial Technology Research Institute (ITRI) will jointly develop, and BTG will commercialise, a polymer technology for information displays for use in the next generation of laptop computers, mobile phones, PDAs and television sets.

BTG seeks to leverage its core IP, technology and commercial expertise by investing in early stage technology companies with high growth potential. An investment in Cambridge-based Xention Discovery Ltd, will develop drug screening programmes in the cardiovascular and neurology areas. BTG will also be a co-sponsor of a new early stage life sciences fund based in Boston, MA.ENDS.

Has it been oversold, that is the question and its a big gamble. I will be watching very carefully early this coming week.

cheers GF.

You avoided the questions goldfinger ....can't you answer them?

Is this thread for positive comments only?

ThirdEye squelched, a well known ramper/re-ramper and trouble maker on all boards on the net, also reported to management. I suggest others do the same.

cheers goldfinger.

I s that your answer to a fair question?


Is your name Arthur Scargill?


How will the interest rates rising affect JCR & it's huge debt?

Do you understand the dilution in the warrants in HCEG?


I know negative comments aren't allowed in your threads, but try answering.

Negative Q are allowed but hey if you have a personal problem with goldfinger take it up with him not on the threads as you are only wasting our time in reading your comment

Well BTG have got of to a positive start, will it last?, I for one will hold off buying until things appear to settle down.

Bema has opened up positively on a good day on the Canadian market Friday.

Thistle has seen profit taking but buyers are coming back into the market, have topped up myself this morning.

cheers GF and have a good day.

Try again

Might get a civil reply:

How will the interest rates rising affect JCR & it's huge debt?

Do you understand the dilution in the warrants in HCEG?


I know negative comments aren't allowed in your threads, but try answering.

goldfinger / third eye,

do you guys have advfn id's?

Just wondered about the history here.

Third eye

You seem to be in the know. Why don't you explain the above? I'd be interested in your views!!

Otherwise stop clogging up the thread.

SH

Yes Andy,
Goldfinger is Oliverleftwingtit aka Slater aka Whitestrike aka Whitelion

Others have said he posts under several usernames on ADVFN.


I'm Outsider on ADVFN.


There is history, I have suggested Cape & Britannia will outperform JCR & they have which has caused many attacks, of course I think JCR has a serious debt issue, & interest rates will affect it. But instead of debate it's abuse or legal action or I'll report you to teacher.

So that is my civil reasonable question....It's negative but not unreasonable.

3 or 4 posts clogging the thread?

I see your in the goldfinger mold too......Isn't it a bit like "GO AWAY I DON'T LIKE NEGATIVE QUESTIONS ABOUT MY STOCKS" ?


Reasonable questions for you guys to answer, I'm sure you have done all your research so you should know.

I cant see thirdeyes attacks as I have squelched him, I suggest you do too. Lets keep this B/Board a place to swap adult like ideas in a civil atmosphere.

cheers Gf.

Had a civil response & accepted it from Bones on the JCR thread.

Will I get one about HCEG on here I wonder?

third eye,

Ok I am familiar with one or two of those logon id's.

I have to admit your questions on here that I have seen are civil, so hopefully you will receive reasonable replies, and we can maintain the standard in this BB that other BB's seem to have abandoned altogether!

I suggest baggage from other BBb's remains there, and we start afresh here.

Happy to do that Andy although you will note I haven't had the same standard from of civility from goldfinger, so you can understand why people get worked up. Perhaps to be fair & equal you should request the same of him?

Even if you don't I will ask reasonable questions & remain civil, as other than the attack I have just witnessed, this seems a civil place to be :-)

Bema staying solid and Thistle mining starting to get strength into the price.

cheers GF.

Well what a lousy day, can tuesday be so bad?. Bring back the Bear lol.

cheers GF.